RP-HPLC METHOD FOR QUANTIFICATION OF PANOBINOSTAT IN PHARMACEUTICAL DOSAGE FORM
Panobinostat in pharmaceutical dosage forms can be quantified using reverse-phase high-performance liquid chromatography (RP-HPLC). It is used in treating cancers, particularly multiple myeloma, as a potent inhibitor of histone deacetylases (HDACs). Using a Symmetry RP-18 column, a mobile phase of sodium dihydrogen phosphate buffer and acetonitrile in a ratio of 85:15 vol/vol at pH 3.5 is used with UV detection at 232 nm. A retention time of 3.40 minutes was obtained under optimized conditions, resulting in sharp, symmetrical peaks. The method demonstrated excellent linearity (r² = 0.999) over the concentration range of 1-11 µg/mL, with a low limit of detection (LOD) of 500 µg/mL and a limit of quantification (LOQ) of 900 µg/mL. Based on precision, accuracy and recovery studies, the method demonstrated a reliability of 99.37% to 100.4%. The column showed good performance, good resolution, and good reproducibility. Despite changes in chromatography conditions, the method exhibited minimal sensitivity. For routine quality control and stability studies, this RP-HPLC method can provide a rapid, accurate, and reproducible analysis of Panobinostat in pharmaceutical formulations
15 , 2 , 2025
17 - 27
Subscriber Login
